Comparative Pharmacology
Head-to-head clinical analysis: BISMUTH SUBSALICYLATE METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE versus TETRACHEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BISMUTH SUBSALICYLATE METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE versus TETRACHEL.
BISMUTH SUBSALICYLATE, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE vs TETRACHEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bismuth subsalicylate exerts antimicrobial and anti-inflammatory effects via binding to gastrointestinal mucosa and inhibiting prostaglandin synthesis; metronidazole inhibits DNA synthesis by forming nitro radical anions; tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
Each dose consists of 2 capsules (each containing bismuth subsalicylate 262.4 mg, metronidazole 250 mg, and tetracycline hydrochloride 375 mg) taken orally 3 times daily (after meals) for 10 days.
500 mg orally once daily for 28 days; for severe infections, 500 mg twice daily for 14 days.
None Documented
None Documented
Bismuth subsalicylate: Bismuth component ~5 days (accumulation risk), salicylate 2–3 hours; Metronidazole: 8 hours (increased in hepatic impairment); Tetracycline HCl: 6–12 hours (prolonged in renal impairment).
6-11 hours (prolonged in renal impairment; up to 57 hours in anuria).
Bismuth subsalicylate: Renal excretion of salicylate and bismuth (bismuth largely fecal as insoluble sulfide); Metronidazole: Renal 60–80% (unchanged and metabolites), fecal 6–15%; Tetracycline HCl: Renal 60% unchanged, fecal 40% (biliary and direct excretion).
Renal 60% (glomerular filtration), fecal 40% (biliary excretion of active drug and metabolites).
Category D/X
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic